Literature DB >> 18936744

Killing two kinase families with one stone.

Benoit Bilanges, Neil Torbett, Bart Vanhaesebroeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18936744     DOI： 10.1038/nchembio1108-648

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN： 1552-4450            Impact factor:   15.040


× No keyword cloud information.
  10 in total

1.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

2.  Measuring and interpreting the selectivity of protein kinase inhibitors.

Authors:  Lynette A Smyth; Ian Collins
Journal:  J Chem Biol       Date:  2009-06-06

3.  Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting.

Authors:  Feng Zhu; Chu Qin; Lin Tao; Xin Liu; Zhe Shi; Xiaohua Ma; Jia Jia; Ying Tan; Cheng Cui; Jinshun Lin; Chunyan Tan; Yuyang Jiang; Yuzong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

Review 4.  Targeting ERK beyond the boundaries of the kinase active site in melanoma.

Authors:  Rachel M Sammons; Ranajeet Ghose; Kenneth Y Tsai; Kevin N Dalby
Journal:  Mol Carcinog       Date:  2019-06-12       Impact factor: 4.784

5.  MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

Authors:  Lingtao Jin; Jaemoo Chun; Chaoyun Pan; Dan Li; Ruiting Lin; Gina N Alesi; Xu Wang; Hee-Bum Kang; Lina Song; Dongsheng Wang; Guojing Zhang; Jun Fan; Titus J Boggon; Lu Zhou; Jeanne Kowalski; Cheng-Kui Qu; Conor E Steuer; Georgia Z Chen; Nabil F Saba; Lawrence H Boise; Taofeek K Owonikoko; Fadlo R Khuri; Kelly R Magliocca; Dong M Shin; Sagar Lonial; Sumin Kang
Journal:  Cancer Cell       Date:  2018-07-19       Impact factor: 31.743

Review 6.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

7.  Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity.

Authors:  Zhengsheng Zhan; Jing Ai; Qiufeng Liu; Yinchun Ji; Tiantian Chen; Yechun Xu; Meiyu Geng; Wenhu Duan
Journal:  ACS Med Chem Lett       Date:  2014-03-26       Impact factor: 4.345

8.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery.

Authors:  Feng Zhu; Zhe Shi; Chu Qin; Lin Tao; Xin Liu; Feng Xu; Li Zhang; Yang Song; Xianghui Liu; Jingxian Zhang; Bucong Han; Peng Zhang; Yuzong Chen
Journal:  Nucleic Acids Res       Date:  2011-09-24       Impact factor: 16.971

9.  Clustered distribution of natural product leads of drugs in the chemical space as influenced by the privileged target-sites.

Authors:  Lin Tao; Feng Zhu; Chu Qin; Cheng Zhang; Shangying Chen; Peng Zhang; Cunlong Zhang; Chunyan Tan; Chunmei Gao; Zhe Chen; Yuyang Jiang; Yu Zong Chen
Journal:  Sci Rep       Date:  2015-03-20       Impact factor: 4.379

10.  Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis.

Authors:  Min Jiang; Yufei Yan; Kai Yang; Zhuochao Liu; Jin Qi; Hanbing Zhou; Niandong Qian; Qi Zhou; Tianqi Wang; Xing Xu; Xiangshu Xiao; Lianfu Deng
Journal:  J Cell Mol Med       Date:  2018-11-20       Impact factor: 5.310
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.